Skip to main content
McMaster University Menu Search

Targeting STAT3: A Therapeutic Option for Medulloblastoma

Targeting STAT3 may provide a novel therapeutic strategy for patients with group 3 and recurrent group 3 medulloblastoma.


Medulloblastoma (MB) is the most common malignant pediatric brain tumour. Despite recent advances in the multimodal treatment of MB, the overall survival remains poor for those with recurrent MB and those diagnosed with the most aggressive medulloblastoma substype, group 3.

In our lab, we have undertaken the exploration of targeting the STAT3 pathway with several novel classes of small molecule inhibitors. Our preliminary data has revealed that targeting STAT3 has significantly diminished proliferative potential of both primary and recurrent medulloblastoma cell lines in vitro, as well as reduced tumorigenic potential in vivo.

Collaborators

Picture Name Organization
Patrick Gunning, PhD Picture Patrick Gunning, PhD Associate Professor, Department of Chemical & Physical Sciences and Department of Chemistry (Graduate Department), University of Toronto Mississauga

Funders

Impacts

Sheila Singh

Sheila Singh

Principal Investigator